AI Hunt for ALS Treatment Continues With 28 Novel Targets Revealed by Insilico Medicine

by Natalia Honchar    Contributor 

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   3553    Comments 0
Topics: Novel Therapeutics   

Insilico Medicine identified 28 new targets for the treatment of amyotrophic lateral sclerosis (ALS) using its proprietary AI-driven platform PandaOmics. Previously unreported 8 genes were shown to have functional connection with ALS and 64% of identified targets were successfully validated in a preclinical animal model. This gives a hope to solve an unmet need for ALS treatment. 
 

Image credit: Insilico Medicine

 

Continue reading

This content available exclusively for BPT Mebmers

Topics: Novel Therapeutics   

Share this:              

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *

SHARE